

Haematologica  
HAEMATOL/2016/147900  
Version 4

Ibrutinib for Relapsed / Refractory CLL: A UK and Ireland Analysis of  
Outcomes in 315 patients

Disclosures: The UK CLL Forum is a charitable body that receives significant funding from the pharma industry including Janssen, Gilead, Roche, GSK, Celgene Dr George Follows has co-ordinated the data collection, analysis and writing of this manuscript. He has received remuneration for advisory board work and lecturing from Janssen, Gilead, Roche, Celgene, GSK, Abbvie. There has been no input from the pharmaceutical industry into the collection / analysis of data, or writing of this paper